期刊
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
卷 27, 期 2, 页码 E118-E124出版社
WICHTIG EDITORE
DOI: 10.5301/JBM.2012.9197
关键词
Interleukin-6; Lung adenocarcinoma; Malignant pleural effusion; Monocyte chemoattractant protein-1; Tumor necrosis factor-alpha; Survival
资金
- Great Medical Research Program of the Nanjing Sanitary Bureau of Jiangsu Province Personalized Therapy of Non Small Cell Lung Cancer Patients
- Jiangsu Province Natural Science Foundation of China [BK2008326]
- Medical Foundation for Distinguished Scholar in Jiangsu Province [RC2007113]
This study aimed at assessing the role of monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in the control of pleural effusion (PE) and survival in patients with primary lung adenocarcinoma. The concentrations of the 3 cytokines were measured in PE from 79 lung adenocarcinoma patients with malignant pleural effusion (MPE) and 23 patients with tuberculosis. Data were correlated with the efficacy of MPE control and patient survival. The level of MCP-1 in PE was significantly higher in patients with lung adenocarcinoma than those with tuberculosis. By contrast, the levels of TNF-alpha and IL-6 were significantly lower in patients with lung adenocarcinoma than those with tuberculosis. An MCP-1 level greater than 3,187 pg/mL (which was used as a cutoff point) indicated failure to control MPE (odds ratio [OR]=2.82, 95% confidence interval [CI]=1.02-7.82, p=0.04). In multivariate analysis, MCP-1 was confirmed as an independent prognostic factor for progression-free survival (hazard ratio [HR]=2.02, 95% CI=1.24-3.30, p=0.01). The level of MCP-1 in PE appears to be a reliable surrogate marker for evaluating the therapeutic efficacy in the control of MPE and predicting survival in lung adenocarcinoma patients with MPE.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据